Answers are grounded in this paper and cite their sources.
Eliciting broadly neutralizing antibodies (bnAbs) remains central in HIV vaccine design, yet vaccines have not induced bnAbs in humans and have had limited success in animal models. A key challenge is converting precursor B-cell recognition into maturation toward conserved epitopes on HIV Env. Here, we show that a three-shot germline-targeting regimen reproducibly activates and matures CDRH3-dominated CD4-binding-site (CD4bs) antibody precursors in CH103-lineage knock-in mice, inducing strong autologous tier-2 and selected heterologous cross-neutralizing serum responses, as well as monoclonal antibodies with tier-2 cross-neutralizing activity. This response is enabled by native-like, membrane-embedded Env arrays on liposomes bearing limited germline-targeting mutations, including the N197D glycan-site mutation, that promote B-cell activation, CH103-class somatic hypermutation, and quaternary Env-antibody recognition. Cryo-electron microscopy of representative antibodies shows recognition of a quaternary CD4bs epitope involving adjacent Env protomers, linking serum neutralization to structural maturation. Env variants that bind multiple CD4bs precursor classes further point to a membrane-Env strategy for multi-lineage germline targeting.
No takes yet. Share an insight, caveat, or question.
Zwick et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: